Natco Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE987B01026
  • NSEID: NATCOPHARM
  • BSEID: 524816
INR
791.40
-4.6 (-0.58%)
BSENSE

Oct 09

BSE+NSE Vol: 2.08 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Marksans Pharma
Alivus Life
Sudeep Pharma
ERIS Lifescience
Pfizer
Concord Biotech
Astrazeneca Phar
Jubilant Pharmo
Natco Pharma
Cohance Life
Alembic Pharma
Why is Natco Pharma Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 12.91% over the last 5 years
2
With a fall in PBT of -50.2%, the company declared Very Negative results in Jun 26
  • The company has declared negative results for the last 3 consecutive quarters
  • NET SALES(Q) At Rs 735.20 cr has Fallen at -27.9% (vs previous 4Q average)
  • PBT LESS OI(Q) At Rs 126.40 cr has Fallen at -57.6% (vs previous 4Q average)
  • PAT(Q) At Rs 206.50 cr has Fallen at -41.8% (vs previous 4Q average)
3
Stock is technically in a Bearish range
  • The technical trend has deteriorated from Mildly Bearish on 25-Aug-26 and has generated -8.25% returns since then
  • Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Natco Pharma for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Natco Pharma
-1.94%
-0.04
37.39%
Sensex
-11.61%
-0.84
13.75%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
12.91%
EBIT Growth (5y)
15.18%
EBIT to Interest (avg)
54.00
Debt to EBITDA (avg)
0.42
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.52
Tax Ratio
8.21%
Dividend Payout Ratio
5.70%
Pledged Shares
0
Institutional Holding
22.61%
ROCE (avg)
21.62%
ROE (avg)
16.51%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
14
Industry P/E
36
Price to Book Value
1.69
EV to EBIT
16.59
EV to EBITDA
13.50
EV to Capital Employed
1.82
EV to Sales
4.08
PEG Ratio
NA
Dividend Yield
0.52%
ROCE (Latest)
15.76%
ROE (Latest)
15.38%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
DEBTORS TURNOVER RATIO(HY)

Highest at 4.63 times

-30What is not working for the Company
NET SALES(Q)

At Rs 735.20 cr has Fallen at -27.9% (vs previous 4Q average

PBT LESS OI(Q)

At Rs 126.40 cr has Fallen at -57.6% (vs previous 4Q average

PAT(Q)

At Rs 206.50 cr has Fallen at -41.8% (vs previous 4Q average

INTEREST(9M)

At Rs 33.40 cr has Grown at 26.04%

ROCE(HY)

Lowest at 15.37%

DEBT-EQUITY RATIO(HY)

Highest at 0.08 times

Loading Valuation Snapshot...
Here's what is working for Natco Pharma
Debtors Turnover Ratio- Half Yearly
Highest at 4.63 times
in the last five half yearly periods
MOJO Watch
Company has been able to settle its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Natco Pharma
Net Sales - Quarterly
At Rs 735.20 cr has Fallen at -27.9% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 1,019.58 Cr
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 126.40 cr has Fallen at -57.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 298.30 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 206.50 cr has Fallen at -41.8% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 354.63 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Interest - Nine Monthly
At Rs 33.40 cr has Grown at 26.04%
over preceding nine months period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Debt-Equity Ratio - Half Yearly
Highest at 0.08 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio